301 related articles for article (PubMed ID: 33576117)
21. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
van Sprundel TC; Schmidt MK; Rookus MA; Brohet R; van Asperen CJ; Rutgers EJ; Van't Veer LJ; Tollenaar RA
Br J Cancer; 2005 Aug; 93(3):287-92. PubMed ID: 16052221
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers.
Hartmann LC; Sellers TA; Schaid DJ; Frank TS; Soderberg CL; Sitta DL; Frost MH; Grant CS; Donohue JH; Woods JE; McDonnell SK; Vockley CW; Deffenbaugh A; Couch FJ; Jenkins RB
J Natl Cancer Inst; 2001 Nov; 93(21):1633-7. PubMed ID: 11698567
[TBL] [Abstract][Full Text] [Related]
23. International rates of breast reconstruction after prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers.
Semple J; Metcalfe KA; Lynch HT; Kim-Sing C; Senter L; Pal T; Ainsworth P; Lubinski J; Tung N; Eng C; Gilchrist D; Blum J; Neuhausen SL; Singer CF; Ghadirian P; Sun P; Narod SA;
Ann Surg Oncol; 2013 Nov; 20(12):3817-22. PubMed ID: 23740344
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer.
Gamble C; Havrilesky LJ; Myers ER; Chino JP; Hollenbeck S; Plichta JK; Kelly Marcom P; Shelley Hwang E; Kauff ND; Greenup RA
Ann Surg Oncol; 2017 Oct; 24(11):3116-3123. PubMed ID: 28699130
[TBL] [Abstract][Full Text] [Related]
25. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer.
Narod SA
Breast Cancer Res Treat; 2011 Jul; 128(2):581-3. PubMed ID: 21455666
[TBL] [Abstract][Full Text] [Related]
26. Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis.
De Felice F; Marchetti C; Musella A; Palaia I; Perniola G; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Ann Surg Oncol; 2015 Sep; 22(9):2876-80. PubMed ID: 25808098
[TBL] [Abstract][Full Text] [Related]
27. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
[TBL] [Abstract][Full Text] [Related]
28. Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy.
Apostolova C; Ferroum A; Alhassan B; Prakash I; Basik M; Boileau JF; Martel K; Meterissian S; Villareal Corpuz V; Wong N; Foulkes WD; Wong SM
Eur J Surg Oncol; 2024 Jun; 50(6):108324. PubMed ID: 38636249
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
30. Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
Saadatmand S; Vos JR; Hooning MJ; Oosterwijk JC; Koppert LB; de Bock GH; Ausems MG; van Asperen CJ; Aalfs CM; Gómez Garcia EB; Meijers-Heijboer H; Hoogerbrugge N; Piek M; Seynaeve C; Verhoef C; Rookus M; Tilanus-Linthorst MM;
Int J Cancer; 2014 Dec; 135(12):2940-9. PubMed ID: 24789418
[TBL] [Abstract][Full Text] [Related]
31. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
32. BRCA1/2 mutation carriers & risk reducing mastectomy: Who undergoes surgery and potential benefits.
Record SM; Thomas SM; Ntowe K; Chiba A; Plichta JK
Am J Surg; 2024 Jan; 227():146-152. PubMed ID: 37827871
[TBL] [Abstract][Full Text] [Related]
33. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
[TBL] [Abstract][Full Text] [Related]
34. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis.
Metcalfe K; Gershman S; Ghadirian P; Lynch HT; Snyder C; Tung N; Kim-Sing C; Eisen A; Foulkes WD; Rosen B; Sun P; Narod SA
BMJ; 2014 Feb; 348():g226. PubMed ID: 24519767
[TBL] [Abstract][Full Text] [Related]
35. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery).
Lodder LN; Frets PG; Trijsburg RW; Meijers-Heijboer EJ; Klijn JG; Seynaeve C; van Geel AN; Tilanus MM; Bartels CC; Verhoog LC; Brekelmans CT; Burger CW; Niermeijer MF
Breast Cancer Res Treat; 2002 May; 73(2):97-112. PubMed ID: 12088120
[TBL] [Abstract][Full Text] [Related]
36. Breast cancer diagnosed after age 70 years in Israeli BRCA1/BRCA2 pathogenic sequence variant carriers: a single institution experience.
Bufman H; Faermann R; Halshtok-Neiman O; Shalmon A; Gotlieb M; Samoocha D; Yagil Y; Feldman DM; Friedman E; Sklair-Levy M
Breast Cancer Res Treat; 2024 Jun; 205(2):281-285. PubMed ID: 38379091
[TBL] [Abstract][Full Text] [Related]
37. MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence Variations.
Lubinski J; Kotsopoulos J; Moller P; Pal T; Eisen A; Peck L; Karlan BY; Aeilts A; Eng C; Bordeleau L; Foulkes WD; Tung N; Couch FJ; Fruscio R; Ramon Y Cajal T; Singer CF; Neuhausen SL; Zakalik D; Cybulski C; Gronwald J; Huzarski T; Stempa K; Dungan J; Cullinane C; Olopade OI; Metcalfe K; Sun P; Narod SA;
JAMA Oncol; 2024 Apr; 10(4):493-499. PubMed ID: 38421676
[TBL] [Abstract][Full Text] [Related]
38. An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers.
Madorsky-Feldman D; Sklair-Levy M; Perri T; Laitman Y; Paluch-Shimon S; Schmutzler R; Rhiem K; Lester J; Karlan BY; Singer CF; Van Maerken T; Claes K; Brunet J; Izquierdo A; Teulé A; Lee JW; Kim SW; Arun B; Jakubowska A; Lubinski J; Tucker K; Poplawski NK; Varesco L; Bonelli LA; Buys SS; Mitchell G; Tischkowitz M; Gerdes AM; Seynaeve C; Robson M; Kwong A; Tung N; Tessa N; Domchek SM; Godwin AK; Rantala J; Arver B; Friedman E
Breast Cancer Res Treat; 2016 Jun; 157(2):319-327. PubMed ID: 27117159
[TBL] [Abstract][Full Text] [Related]
39. Association of premenopausal risk-reducing salpingo-oophorectomy with breast cancer risk in BRCA1/2 mutation carriers: Maximising bias-reduction.
Stjepanovic N; Villacampa G; Nead KT; Torres-Esquius S; Melis GG; Nathanson KL; Teule A; Brunet J; Y Cajal TR; Llort G; Dienstmann R; Rue M; Domchek SM; Balmaña J
Eur J Cancer; 2020 Jun; 132():53-60. PubMed ID: 32325420
[TBL] [Abstract][Full Text] [Related]
40. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.
Rebbeck TR; Friebel T; Lynch HT; Neuhausen SL; van 't Veer L; Garber JE; Evans GR; Narod SA; Isaacs C; Matloff E; Daly MB; Olopade OI; Weber BL
J Clin Oncol; 2004 Mar; 22(6):1055-62. PubMed ID: 14981104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
